PYPD — PolyPid Ltd.

Summary of PolyPid's Q1 2026 Earnings Call

1. Key Financial Results and Metrics:

• Net Loss: $7.7 million, or $0.35 per share, an improvement from a net loss of $8.3 million, or $0.70 per share in Q1 2025.
• Operating Expenses:
  • Research and Development: $5.8 million (down from $6.1 million in Q1 2025).
  • General and Administrative: $1.6 million (up from $1.2 million in Q1 2025).
  • Marketing and Business Development: $0.4 million (up from $0.3 million in Q1 2025).
• Cash Position: $10.9 million as of March 31, 2026, down from $12.9 million at the end of 2025, primarily due to operating activities.
• Debt: Fully repaid remaining loan facility, strengthening the balance sheet ahead of potential commercialization.

2. Strategic Updates and Business Highlights:

• Regulatory Progress: Initiated NDA submission for D-PLEX100 on March 30, 2026, with components submitted and remaining modules expected imminently.
• European Strategy: Scheduled meetings with EMA for MAA submission planned for Q3 2026.
• Commercial Partnership: Discussions with potential U.S. partners are in late stages, focusing on finalizing agreement terms.
• Manufacturing Readiness: Significant resources allocated to ensure compliance and readiness for FDA inspection, with successful mock inspections conducted.
• Clinical Data: Presented promising results at key conferences, including a 64% relative risk reduction in severe wound events from D-PLEX100.

3. Forward Guidance and Outlook:

• 2026 Expectations: Management believes 2026 could be transformative, with ongoing preparations for commercialization and regulatory approvals.
• Cash Resources: Current cash is expected to fund operations into the second half of 2026, covering significant upcoming milestones.

4. Bad News, Challenges, or Points of Concern:

• Market Environment: Ongoing geopolitical tensions in the Middle East could impact FDA inspection timelines, though management remains optimistic about maintaining schedules.
• Regulatory Risks: While there have been no major issues identified in mock inspections, the actual FDA inspection remains a critical hurdle.
• Financial Position: Although the company has a solid cash position, the decrease in cash reserves raises concerns about future funding needs as commercialization approaches.

5. Notable Q&A Insights:

• Management emphasized strong communication with the FDA during NDA preparation, enhancing confidence in the submission process.
• The company is focused on maintaining a disciplined approach to SG&A expenses, with expectations of some increases as commercialization ramps up.
• Discussions around the potential for a broader development pipeline post-commercial partnership, with interest in expanding D-PLEX100's applications and exploring new indications for their PLEX platform.

Overall, PolyPid is navigating a pivotal moment with significant regulatory and commercial developments, while also addressing potential risks and challenges in the current market environment.